ReP USP - Resultado da busca

Artigo de periodico
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes (2019)
Roe, Matthew T; Li, Qian H; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Goodman, Shaun G; Harrington, Robert A; Jukema, J. Wouter; Lopez-jaramillo, Patricio; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: DIRETRIZES PARA A PRÁTICA CLÍNICA, ISQUEMIA MIOCÁRDICA, DISLIPIDEMIAS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROE, Matthew T et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, v. 140, n. 19, p. 1578-1589, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.042551. Acesso em: 13 nov. 2024.
APA
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., et al. (2019). Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 140( 19), 1578-1589. doi:10.1161/CIRCULATIONAHA.119.042551
NLM
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551
Vancouver
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551
Artigo de periodico
Ticagrelor in patients with stable coronary disease and diabetes (2019)
Steg, P. Gabriel; Bhatt, Deepak L; Simon, Tabassome; Fox, Kim; Mehta, Shamir R; Harrington, Robert A; Held, Claes; Andersson, Marielle; Himmelmann, Anders; Nicolau, José Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: CORONARIOPATIA, DIABETES MELLITUS, ADENOSINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, P. Gabriel et al. Ticagrelor in patients with stable coronary disease and diabetes. New england journal of medicine, v. 381, n. 14, p. 1309-1320, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1908077. Acesso em: 13 nov. 2024.
APA
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., et al. (2019). Ticagrelor in patients with stable coronary disease and diabetes. New england journal of medicine, 381( 14), 1309-1320. doi:10.1056/NEJMoa1908077
NLM
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Nicolau JC. Ticagrelor in patients with stable coronary disease and diabetes [Internet]. New england journal of medicine. 2019 ; 381( 14): 1309-1320.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1056/NEJMoa1908077
Vancouver
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Nicolau JC. Ticagrelor in patients with stable coronary disease and diabetes [Internet]. New england journal of medicine. 2019 ; 381( 14): 1309-1320.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1056/NEJMoa1908077
Artigo de periodico
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study (2019)
Bhatt, Deepak L; Fox, Kim; Harrington, Robert A; Leiter, Lawrence A; Mehta, Shamir R; Simon, Tabassome; Andersson, Marielle; Himmelmann, Anders; Ridderstrale, Wilhelm; Nicolau, José Carlos
Source: Clinical cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DIABETES MELLITUS, VASOS CORONÁRIOS, PACIENTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BHATT, Deepak L et al. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical cardiology, v. 42, n. 5, p. 498-505, 2019Tradução . . Disponível em: https://doi.org/10.1002/clc.23164. Acesso em: 13 nov. 2024.
APA
Bhatt, D. L., Fox, K., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., et al. (2019). Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical cardiology, 42( 5), 498-505. doi:10.1002/clc.23164
NLM
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstrale W, Nicolau JC. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study [Internet]. Clinical cardiology. 2019 ; 42( 5): 498-505.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1002/clc.23164
Vancouver
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstrale W, Nicolau JC. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study [Internet]. Clinical cardiology. 2019 ; 42( 5): 498-505.[citado 2024 nov. 13 ] Available from: https://doi.org/10.1002/clc.23164

USP Schools

ReP

Filtros

Authors

Subjects